

**EASDec Conference 2019**

## **PROGRAMME**

**Thursday, 16<sup>th</sup> May 2019**

**VENUE: Church "De Duif", address Prinsengracht 756 in the Amsterdam City Centre**

**15:00 Registration**

**15.30 -16.30: SATELLITE SYMPOSIUM 1  
STANDARDIZATION AND PRACTICAL IMPLEMENTATION OF AI IN DR-  
SCREENING** *Sponsors: IDx, Eyenuk and RetMarker*

**16:30 BREAK**

**16:45 SATELLITE SYMPOSIUM 2  
ANTI-VEGF IN DME AND PROLIFERATIVE DIABETIC RETINOPATHY: NEW  
DEVELOPMENTS** *Sponsor: Novartis*

**Chair: Hans Vingerling**

**16.45-17.00 N Davies (UK)**

Practical implementation of comparative RCT's in proliferative DR: Clarity and Protocol S study results

**17.00-17.15 Janneke van Lith (Netherlands)**

Comparing the efficacy of bevacizumab to ranibizumab in patients with diabetic macular edema: The BRDME study

**17.15-17.30 Reinier Schlingemann (Netherlands)**

Practical implementation of comparative RCT's in DME: Protocol T and BRDME results

**17.30-17.45 Ursula Schmidt-Erfurth (Austria)**

Automated analysis of OCT images in the treatment of diabetic retinopathy

**17.45-18.00 Panel discussion**

**18.00 Symposium ends**

**Official opening of EASDec and the Annual Meeting Welcome Reception**

**VENUE: Church "De Duif" in the Amsterdam City Centre**

18.00 - 19.30 Drinks reception and canapés  
Advice on restaurants - recommend prebooking

**FRIDAY, 17<sup>th</sup> MAY 2019**

**VENUE: Amsterdam UMC, location Academic Medical Center (AMC), address Meibergdreef 9 in Amsterdam**

08.00 Registration

**09.00 INTRODUCTION AND WELCOME**

**Professor Reinier Schlingemann/Professor Rafael Simó**

**SESSION 1: NEW CLINICAL PERSPECTIVES**

Chaired by: **Dr. Stela Vujosevic and Prof. Jakob Grauslund**

***Moderator's introduction of the session***

**1 – van der Heijden, A (Netherlands)**

**Abstractid: 33**

Retinopathy prediction models in type 2 diabetes: Systematic review and external validation study

**2 - Simó-Servat, O (Spain)**

**Abstractid: 4**

Usefulness of gaze fixation assessment for identifying subjects with type 2 diabetes at risk of dementia

**3 – van Romunde, S (Netherlands)**

**Abstractid: 38**

Prevalence and severity of diabetic retinopathy in patients with MacTEL type 2

**4 – Stratton, I (UK)**

**Abstractid: 44**

Aflibercept in the real world – a clinical audit of people with diabetic macular edema from 21 UK hospitals

**5 – Konstantinidis, L (Switzerland)**

**Abstractid: 46**

Evaluation of retinal function assessed with a novel handheld instrument (RETeval) using flicker electroretinography after anti-VEGF treatment in patients with diabetic macular oedema

**10.15 Introduction to EVA KOHNER LECTURE: Professor Reinier Schlingemann**

**10.18 EVA KOHNER LECTURE: Professor Alan Stitt**

10.55 Coffee/tea break

## **11.25 SESSION 2: STUDIES ON VITREOUS OR AQUEOUS HUMOUR SAMPLES TO UNDERSTAND DIABETIC EYE DISEASE**

Chaired by: **Professor Rafael Simó and Professor Alan Stitt**

### **11.25 Moderator's introduction of the session**

#### **1 – Simó, R (Spain)**

##### **Abstractid: 5**

Usefulness of liquid biopsy of aqueous humour biomarkers in predicting anti-VEGF response in diabetic macular oedema: Results of a pilot study

#### **2 – Friedrich, J (Netherlands)**

##### **Abstractid: 26**

Expression profiles of microRNAs in the vitreous of proliferative diabetic retinopathy patients and differences with patients treated with anti-VEGF therapy

#### **3 – Klaassen, I (Netherlands)**

##### **Abstractid: 54**

Differential protein levels in vitreous of proliferative diabetic retinopathy patients treated with aflibercept and bevacizumab

## **Keynote 1: Max Nieuwdorp (Netherlands): The role of microbiome in health and disease**

### **12.40 Lunch**

*(Poster presenters have priority for lunch)*

## **13.15 SESSION 3: POSTER SESSION**

### **DR Screening:**

**Moderators: Dr. Irene Stratton and Dr. Olga Simo-Servat**

#### **1 - Lopez Galvez, MI (Spain)**

##### **Abstractid: 1**

Teleophthalmology screening programme for DR based on a centralised reading centre: Patient and healthcare professionals' satisfaction with the grading?"

#### **2 – Wharton, H (UK)**

##### **Abstractid: 9**

Should we photograph eyes with perception of light and no perception of light during diabetic eye screening?

#### **3 – Almeida, N (Portugal)**

##### **Abstractid: 15**

Retmarker screening: new image quality algorithm immediately evaluates gradeability of images

#### **4 – Erke, MG (Norway)**

##### **Abstractid: 16**

## Screening for diabetic retinopathy at an outpatient diabetes centre in Norway

### **5 – Byberg, S (Denmark)**

#### **Abstractid: 20**

Evaluating a screening algorithm for diabetic retinopathy and the effect of glycaemic dysregulation

### **6 – Hamill, B (UK)**

#### **Abstractid: 29**

The comparison between an automated reading and human grading of images from a handheld wide field imaging device

### **7 – Changulani, T (UK)**

#### **Abstractid: 34**

Referral to treatment guidelines for proliferative diabetic retinopathy in Scotland: are they possible?

### **8 – Hamid, A (UK)**

#### **Abstractid: 41**

Why do patients default eye clinic appointments after referral from the screening programme?

### **9 – Dale, A (UK)**

#### **Abstractid: 49**

Diabetic maculopathy levels in an English county

## **Clinical aspects and risk factors**

*Moderators to be confirmed*

### **1 – Lipatov, D (Russia)**

#### **Abstractid: 6**

Dynamics of diabetic retinopathy in Russia in 2014-2017 years

### **2 – Stefansson, E (Iceland)**

#### **Abstractid: 8**

Smart phone APP for individual risk assessment for progression of diabetic retinopathy

### **3 – Pomytkina, N (Russia)**

#### **Abstractid: 18**

Progression of diabetic retinopathy in pregnant women with type 1 diabetes

### **4 – Grauslund, J (Denmark)**

#### **Abstractid: 19**

DECODE EYE – Ocular and systemic complications in diabetic retinopathy

### **5 – Tomić, M (Croatia)**

#### **Abstractid: 28**

Adipocytokines and obesity are associated with endothelial dysfunction and retinopathy development in type 1 diabetes

### **6 – Palarie, N (Moldova)**

#### **Abstractid: 53**

## Association of obesity and retinopathy in type 2 diabetes

### **DR treatment**

*Moderators to be confirmed*

#### **1 – Kotagiri, A (UK)**

##### **Abstractid: 3**

Baseline characteristics from an observational study (DRAKO) investigating outcomes of Intravitreal aflibercept injections for treatment of diabetic macular oedema (DMO) in the UK

#### **2 – Vergmann, AS (Denmark)**

##### **Abstractid: 30**

Effect of panretinal photocoagulation with navigated laser on visual field in patients with treatment-naïve proliferative diabetic retinopathy

#### **3 – Blindbæk, S (Denmark)**

##### **Abstractid: 35**

Aflibercept and navigated versus conventional laser in diabetic macular oedema

#### **4 – Celik, E (Turkey)**

##### **Abstractid: 36**

Efficacy of intravitreal dexamethasone implant treatment in diabetic macular oedema refractory to intravitreal aflibercept treatment

### **Laboratory and clinical experimental studies**

**Moderators: Dr Luisa Ribeiro and Dr Nicola Quinn**

#### **1 – Bashina, I (Russia)**

##### **Abstractid: 7**

Association between aqueous cytokines and diabetic retinopathy stage

#### **2 – Mazzeo, A (Italy)**

##### **Abstractid: 12**

High glucose and hypoxia-induced damage in the inner blood retinal barrier is counteracted by thiamine supplementation

#### **3 – Balyen, LSD (Turkey)**

##### **Abstractid: 37**

Castanea sativa extract has anti-oxidative properties: an experimental study with retinas of metabolic syndrome-induced rats

#### **4 – Balyen, L (Turkey)**

##### **Abstractid: 40**

Protective effect of *Onosma nigricaula* (Boraginaceae) on retinal oxidative and nitrosative stress in rats with metabolic syndrome

#### **5 - Lund-Andersen, H (Denmark)**

##### **Abstractid: 43**

Dark adaptation in humans leads to reduced oxygen saturation in the nasal peripheral retinal veins as measured with oximetry

## **6 – Gooding, K (Netherlands)**

### **Abstractid: 50**

A preliminary study examining albuminuria, macular thickness and glycocalyx shedding in the early stages of diabetic retinopathy in type 2 diabetes

## **2.50 SESSION 4: AUTOMATED GRADING**

**Chaired by: Professor Simon Harding and Dr. Frank Verbraak**

### ***Moderators' introduction of the session***

#### **1 – Pratt, H (UK)**

##### **Abstractid: 52**

Learning the features of diabetic retinopathy with convolutional neural networks

#### **2 – Ramos, J (Portugal)**

##### **Abstractid: 14**

Retmarker screening: alternative deep learning algorithm also increases burden reduction in diabetic retinopathy screening programs

#### **3 – Harding, S (UK)**

##### **Abstractid: 45**

The costs of screening for sight-threatening diabetic retinopathy

## **3.35 SESSION 5: TREATMENT OF DME**

**Chaired by: Dr Erke Maja Gran and Professor Lund Andersen**

#### **1 – Capone, L (Italy)**

##### **Abstractid: 22**

Fluocinolone acetonide 0.2µg/day (Iluvien®) for the treatment of chronic diabetic macular oedema: an Italian real-world experience

#### **2 – Parker, N (Northern Ireland)**

##### **Abstractid: 23**

Use of Iluvien implant for diabetic macular oedema in the Belfast Health and Social Care Trust, Northern Ireland

#### **3 – Eandi, CM (Italy)**

##### **Abstractid: 27**

Characteristics of diabetic macular oedema recurrence according to different baseline OCT patterns in patients treated with dexamethasone Implant

#### **4 – Schlingemann, RO (Netherlands)**

##### **Abstractid: 51**

Comparing the efficacy of bevacizumab to ranibizumab in patients with diabetic macular edema: The BRDME study.

#### **5 – Vader, MJC (Netherlands)**

##### **Abstractid: 32**

Cost-utility of bevacizumab versus ranibizumab in patients with diabetic macular edema: analysis from the BRDME study

#### **4.45 Debate: Corticosteroids vs anti-VEGF in DME tbc**

#### **5.10 ANNUAL GENERAL MEETING**

Moderator: **Professor Reinier Schlingemann/ Dr Stela Vujosevic**

**Including 5.15 -5.20: Dr Lokman Balyen: Presentation from the winner of the 2017 EASDec skills award**

#### **7.00 CONFERENCE DINNER**

**VENUE: Hermitage, address Amstel 51 in the Amsterdam City Center**

**SATURDAY, 18<sup>th</sup> MAY 2019**

**VENUE: Amsterdam UMC, location Amsterdam Medical Center (AMC), address Meibergdreef in Amsterdam**

08.30 Registration

#### **09.00 SESSION 6: LAB – session 2**

**Chaired by: Dr Ingeborg Klaassen and Prof. Reinier Schlingemann**

***Moderators' introduction of the session***

##### **1 – Fresia, D (Switzerland)**

**Abstractid: 13**

Role of ER stress in hypoglycaemia-induced mouse retina cell death

##### **2 – Porcu, M (Belgium)**

**Abstractid: 24**

Cell-type specific insights into the Akimba model of diabetic retinopathy using single cell transcriptomics analysis

##### **3 – Cagiltay, E (Turkey)**

**Abstractid: 48**

Choroidal thickness significantly changes after oral glucose tolerance test in subjects with prediabetes: a spectral domain optical coherence tomography study

##### **4 – Ribeiro, L (Portugal)**

**Abstractid: 10**

Multimodal imaging of the initial stages of diabetic retinopathy. Different disease pathways in different patients

**5 - Winner of the best student abstract price – Eyre, JJ (UK)**

**Abstractid: 47**

Incorporation of endothelial colony forming cells into an *in vitro* human primary co-culture model of diabetic retinopathy

**10.25 KEYNOTE LECTURE: Dr. Ingeborg Klaassen: Liquid biopsy and diabetic retinopathy**

*Coffee/tea break*

**11.30 SESSION 7: Imaging**

**Chaired by: Dr. Ali Erginay and Dr. Amber van der Heijden**

***Moderators' introduction of the session***

**1 – Vujosevic, S (Italy)**

**Abstractid: 11**

Early detection of microvascular changes in patients with diabetes mellitus without and with diabetic retinopathy: comparison between different swept-source OCT-A instruments

**2 – Erginay, A (France)**

**Abstractid: 39**

Rapid macular capillary loss in young patients with uncontrolled type 1 diabetes

**3 – Quinn, N (Northern Ireland)**

**Abstractid: 25**

Clinical characteristics of the peripheral retina in people with diabetes

**4 – Byberg, S (Denmark)**

**Abstractid: 31**

Optos wide-field imaging versus conventional camera imaging in Danish patients with type 2 diabetes

**5 – Hafner, J (Austria)**

**Abstractid: 2**

Presence of peripheral lesions and correlation to macular perfusion, oxygenation and neurodegeneration in early type 2 diabetic retinal disease

**Debate: Fundus fluorescein angiography versus imaging the diabetic eye with OCT-A and/or widefield imaging**

**FFA: Prof. Jakob Grauslund**

**OCT-A/wide field imaging: tbc**

**12.45 Best poster prize ceremony and closing remarks**

**Professor Rafael Simó**